Tue, August 4, 2009
Mon, August 3, 2009
Sat, August 1, 2009
Fri, July 31, 2009
Thu, July 30, 2009
Wed, July 29, 2009
Tue, July 28, 2009
Mon, July 27, 2009
Sat, July 25, 2009
Fri, July 24, 2009
Thu, July 23, 2009
Wed, July 22, 2009
Tue, July 21, 2009
Mon, July 20, 2009
Sun, July 19, 2009
Fri, July 17, 2009
Thu, July 16, 2009
Wed, July 15, 2009
Tue, July 14, 2009
Mon, July 13, 2009
Fri, July 10, 2009
Thu, July 9, 2009
Wed, July 8, 2009
Tue, July 7, 2009
Mon, July 6, 2009
Fri, July 3, 2009
Thu, July 2, 2009
Wed, July 1, 2009
Tue, June 30, 2009
Mon, June 29, 2009
Fri, June 26, 2009
Thu, June 25, 2009
Wed, June 24, 2009
Tue, June 23, 2009
Mon, June 22, 2009
Sun, June 21, 2009
Fri, June 19, 2009
Thu, June 18, 2009
Wed, June 17, 2009
Tue, June 16, 2009
Mon, June 15, 2009
Fri, June 12, 2009
Thu, June 11, 2009
Wed, June 10, 2009
Tue, June 9, 2009
Mon, June 8, 2009
Sun, June 7, 2009
Fri, June 5, 2009
Thu, June 4, 2009
Wed, June 3, 2009
Tue, June 2, 2009
Mon, June 1, 2009
Sat, May 30, 2009
Fri, May 29, 2009
Thu, May 28, 2009
Wed, May 27, 2009
Tue, May 26, 2009

Pharming Group N.V.: Pharming confirms positive results from final analysis of Rhucin(R) studies


//health-fitness.news-articles.net/content/2009/ .. lts-from-final-analysis-of-rhucin-r-studies.html
Published in Health and Fitness on Tuesday, June 30th 2009 at 23:34 GMT, Last Modified on 2009-06-30 23:35:24 by Market Wire   Print publication without navigation


LEIDEN, NETHERLANDS--(Marketwire - July 1, 2009) -


Leiden, The Netherlands, July 1, 2009. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that, as part of the activities for the regulatory submission files, it has now also completed the final analysis of its Rhucin® randomised placebo-controlled studies. The results confirm the positive and consistent efficacy and safety of Rhucin in the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE).

Pharming conducted two independent, randomized, double blind, placebo controlled clinical studies in Europe and in North-America (US and Canada). In total, 70 attacks were randomized to one of two doses of Rhucin (100 U/kg, 50 U/kg body weight) or placebo control treatment. Of these 70 patients, 32 were treated in the European study and 38 patients in the North-American study. The final statistical analyses have now been undertaken in line with the latest EU and US regulatory guidance. Both studies independently demonstrated statistically significant and clinically relevant results on primary and secondary endpoints, thus demonstrating the efficacy of Rhucin for the treatment of acute attacks of Hereditary Angioedema.

In the EU study, time to onset of relief (median), the primary endpoint, was 62 minutes for Rhucin 100 U/kg compared to 508 minutes for control treatment. In the North America study, time to onset of relief (median) was 68 and 122 minutes respectively for Rhucin 100 and 50 U/kg compared to 258 minutes for control treatment. In the EU study, time to minimal symptoms (median), the secondary endpoint, was 480 minutes for Rhucin 100 U/kg compared to 1440 for control treatment. In the North America study, time to minimal symptoms (median) was 245 and 247 minutes respectively for Rhucin 100 and 50 U/kg compared to 1101 for control treatment. None of the Rhucin treated patients experienced a relapse of symptoms in the same attack.

As to safety, no clinically relevant concerns were reported in either study. There were no drug-related serious adverse events, no allergic reactions, and, no immuno-safety concerns due to antibody responses to Rhucin or rabbit milk proteins. Rhucin infusions were well tolerated, without reports of pain or irritation at the injection site. Together with the evaluation of the open-label studies and other studies reported previously, the Rhucin safety database now includes over 300 treatments of acute attacks.

"The results from these studies demonstrate Rhucin's excellent efficacy and safety profile in treating acute attacks of HAE," said Marco Cicardi, MD, Professor of Internal Medicine at the University of Milan, Italy and Principal Investigator of the European trial. "Having a recombinant human C1 inhibitor protein, such as Rhucin, as a treatment option for HAE is a notable advance in the field that will be important to both patients and physicians."

"Rhucin has shown to safely provide rapid and sustained relief of symptoms in HAE patients having acute attacks. We believe that our current clinical database adequately supports the efficacy and safety of Rhucin, in single and repeated use, in acute attacks at all anatomical locations, including laryngeal attacks," said Bruno Giannetti, Chief Operations Officer of Pharming. "With the European regulatory agency recently agreeing on the pediatric investigation plan for Rhucin in HAE and the recently reported immuno-safety data, we are on schedule to submit our European Union Marketing Authorization Application for Rhucin in September 2009."

The open-label extension studies of Rhucin are ongoing in HAE patients for the treatment of acute attacks. Over 380 acute angioedema attacks of all types in over 130 patients have now been treated including many potentially life-threatening laryngeal attacks. More than 25 HAE patients have been treated at least 4 times and one HAE patient has been treated 25 times.


About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® for Hereditary Angioedema and human Lactoferrin for use in food products and one product in early stage clinical development - Prodarsan® for Cockayne Syndrome. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, [ http://www.pharming.com ].


This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.


 Contact: Sijmen de Vries, Pharming Group NV, T: +31 (0)71 52 47 400 Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431 

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.


Publication Contributing Sources